Date: 2015-11-24 01:50:17Lung cancer Clinical medicine Cancer Tyrosine kinase inhibitors Boehringer Ingelheim Health T790M Protein kinase inhibitor Epidermal growth factor receptor Non-small-cell lung carcinoma Targeted therapy | | ZAI Lab and Hanmi execute a license agreement to develop novel EGFR targeted therapy for lung cancer in China Shanghai, China and Seoul, Korea, 23th November 2015 – ZAI Lab Limited and Hanmi Pharm. Co., Ltd. announced Add to Reading ListSource URL: www.zailaboratory.comDownload Document from Source Website File Size: 225,61 KBShare Document on Facebook
|